JP2024503898A5 - - Google Patents

Info

Publication number
JP2024503898A5
JP2024503898A5 JP2023544070A JP2023544070A JP2024503898A5 JP 2024503898 A5 JP2024503898 A5 JP 2024503898A5 JP 2023544070 A JP2023544070 A JP 2023544070A JP 2023544070 A JP2023544070 A JP 2023544070A JP 2024503898 A5 JP2024503898 A5 JP 2024503898A5
Authority
JP
Japan
Application number
JP2023544070A
Other languages
Japanese (ja)
Other versions
JPWO2022159976A5 (https=
JP2024503898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/070308 external-priority patent/WO2022159976A1/en
Publication of JP2024503898A publication Critical patent/JP2024503898A/ja
Publication of JP2024503898A5 publication Critical patent/JP2024503898A5/ja
Publication of JPWO2022159976A5 publication Critical patent/JPWO2022159976A5/ja
Pending legal-status Critical Current

Links

JP2023544070A 2021-01-22 2022-01-24 ラパマイシン類似体及びその使用 Pending JP2024503898A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163140523P 2021-01-22 2021-01-22
US63/140,523 2021-01-22
US202163202524P 2021-06-15 2021-06-15
US63/202,524 2021-06-15
PCT/US2022/070308 WO2022159976A1 (en) 2021-01-22 2022-01-24 Rapamycin analogs and uses thereof

Publications (3)

Publication Number Publication Date
JP2024503898A JP2024503898A (ja) 2024-01-29
JP2024503898A5 true JP2024503898A5 (https=) 2025-02-03
JPWO2022159976A5 JPWO2022159976A5 (https=) 2025-02-03

Family

ID=82549982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544070A Pending JP2024503898A (ja) 2021-01-22 2022-01-24 ラパマイシン類似体及びその使用

Country Status (9)

Country Link
US (1) US20220267352A1 (https=)
EP (1) EP4281463A4 (https=)
JP (1) JP2024503898A (https=)
KR (1) KR20230136625A (https=)
AU (1) AU2022209863A1 (https=)
BR (1) BR112023014287A2 (https=)
CA (1) CA3209086A1 (https=)
MX (1) MX2023008634A (https=)
WO (1) WO2022159976A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3914245A4 (en) 2019-01-22 2022-08-24 Aeovian Pharmaceuticals, Inc. MTORC-1 MODULATORS AND USES THEREOF
WO2021195599A1 (en) 2020-03-27 2021-09-30 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935110B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
JP2010500286A (ja) * 2006-07-25 2010-01-07 アボット・ラボラトリーズ 結晶形態のラパマイシン類似体
WO2011130232A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
EP2601201B1 (en) * 2010-08-04 2014-09-24 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
US10683308B2 (en) * 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
IL314362A (en) * 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
EP3914245A4 (en) * 2019-01-22 2022-08-24 Aeovian Pharmaceuticals, Inc. MTORC-1 MODULATORS AND USES THEREOF
KR20220128345A (ko) * 2019-12-05 2022-09-20 아나쿠리아 테라퓨틱스, 인코포레이티드 라파마이신 유사체 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2024503898A5 (https=)
BR102023007252A2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
CN307044466S (https=)
CN307049998S (https=)
CN307049181S (https=)
CN307047953S (https=)
CN307047867S (https=)
CN307047738S (https=)
CN307047689S (https=)
CN307047587S (https=)
CN307047304S (https=)
CN307045618S (https=)
CN307045090S (https=)
CN307044944S (https=)
CN307044940S (https=)
CN307044769S (https=)
CN307044615S (https=)
CN307044341S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)